Even its topical application helps in the regression of cutaneous T-cell lymphoma or CTCL (malignant T cells accumulate in the chronically inflamed skin) due to the TLR7-mediated activation of DCs, increased skin T cell effector functions, and the increased cytolytic action of the natural killer or NK cells (Brunner et al., 2020[18]; Rook et al., 2015[168]; Stolearenco et al., 2020[197]). This evidence concerns the gene TLR7 and primary cutaneous T-cell non-Hodgkin lymphoma.